Cabaletta Bio, Inc. (CABA)

Current Report Filed: 2026-05-14

Key Insights

Rese-cel demonstrated compelling drug-free clinical responses in 2 of 4 lowest-dose patients with pemphigus vulgaris without preconditioning, with similar CAR T cell expansion kinetics to preconditioned patients, suggesting potential to broaden patient reach and reduce treatment burden.
Automated manufacturing using Cellares Cell Shuttle platform successfully replicated process consistency with first two GMP doses meeting all release specifications, supporting scalable commercial supply with minimal capital investment if approved.
Company expects additional data from higher PC-free doses in H2 2026 and initial RESET-SLE data in 1H 2026, providing near-term catalysts for clinical validation and potential expansion into other autoimmune indications beyond pemphigus vulgaris.

Current Report Filed: 2026-05-14

Key Insights

Cabaletta Bio announced Q1 2026 financial results on May 14, 2026, with the full details provided in an attached press release that was furnished but not filed, limiting its regulatory weight.
The 8-K filing itself contains minimal substantive information, serving primarily as a vehicle to disclose earnings results rather than a material event or corporate action.
As a clinical-stage biotech company, investors should focus on the press release details regarding pipeline progress, cash position, and burn rate rather than the 8-K structure itself, which provides no operational insights.

Quarterly Report Filed: 2026-05-14

Key Insights

The filing content appears corrupted or improperly formatted, containing only XML metadata tags and dimensional members without actual financial statements, making it impossible to extract concrete financial metrics, revenue figures, or operational performance data.
Multiple references to financing activities including May 2025 and June 2025 financing transactions, plus at-the-market (ATM) offering agreements, suggest the company is actively raising capital and may be experiencing ongoing liquidity management needs.
The presence of numerous stock option and warrant-related disclosures indicates significant dilution from equity compensation and warrant exercises, which could impact shareholder ownership percentages and earnings per share calculations.
References to license agreements, development agreements with Lonza, and sponsored research agreements suggest ongoing R&D commitments and partnerships, typical for a clinical-stage biotech company focused on cell therapy development.

Current Report Filed: 2026-03-23

Key Insights

Cabaletta Bio reported its Q4 2025 and full-year 2025 financial results, providing investors with an update on the company's financial performance and operational progress.
The company posted an updated corporate presentation, which likely contains new information on its pipeline, milestones, and strategic initiatives that investors should review.
Investors should monitor any potential changes in Cabaletta's leadership team or key personnel, as management transitions can impact a company's direction and execution.

Annual Report Filed: 2026-03-23

Key Insights

Cabaletta Bio, Inc. (CABA) appears to be a clinical-stage biotechnology company focused on the development of novel T cell therapies for autoimmune diseases. The company has several licensing agreements and strategic partnerships, indicating potential collaborations and growth opportunities.
The 10-K filing highlights Cabaletta's ongoing research and development activities, with a focus on its lead product candidate for pemphigus vulgaris. This suggests the company is making progress in advancing its pipeline.
The company reported an increase in general and administrative expenses, which could indicate the need for additional funding or the expansion of its operations. Investors should monitor the company's cash position and financing activities.

Insider Trading Filed: 2026-01-21

Key Insights

Michael Gerard, the General Counsel of Cabaletta Bio, Inc. (CABA), purchased 6,600 shares of the company's common stock on January 21, 2026 at a weighted average price of $2.2696 per share.
This insider buying activity may signal Gerard's confidence in the company's future prospects and could be viewed positively by investors.
The transaction amount is relatively small, suggesting it may not be a significant event, but it still provides insight into the company's leadership's perspective on the stock's valuation.

Insider Trading Filed: 2026-01-21

Key Insights

Insider Mark Simon purchased 11,061 shares of Cabaletta Bio, Inc. (CABA) at an average price of $2.2838, increasing his direct ownership to 147,205 shares.
Simon also owns an additional 7,000 shares indirectly through his spouse, indicating a sizable and growing personal stake in the company.
The insider purchase suggests Simon's confidence in Cabaletta Bio's prospects and aligns his interests with those of other shareholders.

Insider Trading Filed: 2026-01-21

Key Insights

The reporting person, Steven Nichtberger, who is the President and CEO of Cabaletta Bio, Inc., has directly acquired 45,000 shares of the company's common stock at a weighted average price of $2.2395 per share.
Nichtberger also holds an indirect beneficial ownership of 363,000 shares through the 2017 Nichtberger Family Trust.
This insider buying activity could be a positive signal for investors, as the CEO is demonstrating confidence in the company's prospects by increasing his personal stake.

Insider Trading Filed: 2026-01-21

Key Insights

Catherine Bollard, a director of Cabaletta Bio, Inc., acquired 4,405 shares of the company's common stock on January 21, 2026 at a price of $2.2661 per share.
This purchase increases Bollard's direct beneficial ownership to 5,405 shares of Cabaletta's common stock.
Insider buying, especially by directors, can be a positive signal about the company's prospects and potential future performance.

Insider Trading Filed: 2026-01-21

Key Insights

Steve Gavel, the Chief Commercial Officer of Cabaletta Bio, Inc. (CABA), has directly purchased 22,170 shares of the company's common stock on January 21, 2026 at a weighted average price of $2.265 per share.
This insider buying activity suggests that Gavel has confidence in the company's future prospects and is willing to invest his own capital in the stock.
The purchase of a sizable number of shares by a key executive could signal positive sentiment within the company and may be viewed favorably by investors.

Insider Trading Filed: 2026-01-21

Key Insights

Insider Shawn Tomasello acquired 22,725 shares of Cabaletta Bio, Inc. (CABA) at $2.2144 per share, indicating his confidence in the company's prospects.
The transaction represents a direct ownership increase for Tomasello, further aligning his interests with those of other shareholders.
Insider buying of this magnitude can be viewed as a positive signal, as insiders typically have superior information about the company's future performance.

Insider Trading Filed: 2026-01-21

Key Insights

Insider Gwendolyn Binder, the President of Science and Technology, purchased 11,312 shares of Cabaletta Bio, Inc. (CABA) at $2.1891 per share, indicating confidence in the company's prospects.
This insider purchase represents a direct ownership increase of 56.4% for Binder, signaling a positive view on the company's future performance.
Insider buying is often seen as a positive signal, as it suggests the reporting person believes the stock is undervalued and has potential for future growth.

Insider Trading Filed: 2026-01-21

Key Insights

The reporting person, David J. Chang, the Chief Medical Officer of Cabaletta Bio, Inc., has acquired 8,800 shares of the company's common stock at a price of $2.26 per share.
This purchase suggests that the insider has a positive outlook on the company's future prospects and is willing to increase their ownership stake.
The timing of the transaction, which occurred on January 21, 2026, may indicate the insider's confidence in the company's near-term performance or upcoming events.

Current Report Filed: 2026-01-12

Key Insights

Cabaletta Bio has initiated a registrational cohort for its rese-cel therapy in dermatomyositis and antisynthetase syndrome, which affects about 70,000 patients in the US, with the potential to submit a Biologics License Application next year.
The company has aligned with the FDA on registrational cohort designs for evaluating rese-cel in systemic lupus erythematosus and lupus nephritis, with updates expected later this year.
Cabaletta is advancing its fully automated, scalable manufacturing for rese-cel using Cellares' Cell Shuttle and Cell Q technology, which could enable rapid global expansion and lower manufacturing costs post-commercialization.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information